SCHEMBL3880941

SCHEMBL3880941

CC(C)(C)OC(=O)N1CCN(c2ncnc3c2ncn3Cc2ccccc2C#N)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.46
CNR2 P34972 1/20 0.46
HRH4 Q9H3N8 1/20 0.46
KIT P10721 2/20 0.45
GPR119 Q8TDV5 4/20 0.45
PIK3CD O00329 1/20 0.44
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
NSD2 O96028 1/20 0.41
KCNH2 Q12809 1/20 0.41
MAP4K4 O95819 1/20 0.40
ACHE P22303 1/20 0.39
SLC29A1 Q99808 1/20 0.39
DPP4 P27487 1/20 0.39
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879222 0.84 CNR1 (0.53) CNR1CNR2KITGPR119PIK3CD
SCHEMBL3874490 0.81 KIT (0.47) CNR1CNR2KITGPR119NR1H2
SCHEMBL23977295 0.79 HRH4 (0.49) CNR1CNR2HRH4KITGPR119
SCHEMBL17274907 0.78 HRH4 (0.51) CNR1CNR2HRH4KITSLC29A1
SCHEMBL30225418 0.77 CNR1 (0.44) CNR1CNR2HRH4KITGPR119
SCHEMBL23977314 0.77 CNR1 (0.44) CNR1CNR2HRH4KITGPR119
SCHEMBL23552036 0.75 VEGFA (0.47) GPR119NSD2
SCHEMBL3877546 0.74 PIK3CD (0.59) CNR1CNR2KITGPR119PIK3CD
SCHEMBL3538823 0.74 KDM4E (0.59) KITGPR119NR1H2NR1H3
SCHEMBL652792 0.73 GRM5 (0.53) GPR119CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524847-B2 Fused 1,3-dihydro-imidazole ring compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed
US-7524847-B2 Fused 1,3-dihydro-imidazole ring compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed
US-7524847-B2 Fused 1,3-dihydro-imidazole ring compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed
US-20060111362-A1 1,3-Dihydroimidazole ring compound EISAI CO., LTD. (JP) 2006-05-25 US disclosed
EP-1568699-A1 1,3-DIHYDROIMIDAZOLE FUSED-RING COMPOUND Eisai Co., Ltd. (JP) 2005-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111362-A1 1,3-Dihydroimidazole ring compound NR2C2, NR0B2, DPP4 CNR1 560/4885CNR2 570/4885HRH4 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.